SparingVision
French tech company | Builders Republic
About
Clinical-stage gene therapy company developing mutation-independent neuroprotective treatments for blinding retinal diseases — lead candidate SPVN06 targets Retinitis Pigmentosa (PRODYGY trial completed), secondary program SPVN20 addresses dry Age-Related Macular Degeneration and Geographic Atrophy.
Key facts
- Status
- Active
- Sectors
- Healthcare & Life Sciences
- Latest stage
- Series B
- Founded
- 2016
- City
- PARIS
- Region
- IDF
- Legal name
- SPARINGVISION
- SIREN
- 821148327
- Tracked rounds
- 2
- Amount raised
- 120 M€ raised since 2020
Recognition
- French Tech 120
Funding rounds
- Series B — 2022
- Series B — 2020
Investors
- 4BIO Capital
- bpifrance
- Foundation Fighting Blindness
- Jeito Capital
- Pittsburgh Medical Center Enterprise
- University Pittsburgh Medical Center Enterprises
- Ysios Capital